News

Today, the FDA approved the abacavir, dolutegravir, and lamivudine single tablet formulation Triumeq, a once-daily HIV treatment for children.

The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).

The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.

“Together these 2 diseases create a perfect storm”: Black people with cancer were more likely to have severe or fatal COVID-19 disease.

New policy appears inconsistent and, on the surface, unfair, expert says.

Today, the FDA approved the long-acting HIV treatment Cabenuva (cabotegravir and rilpivirine dually administered) for virologically suppressed adolescents 12 years and older.

The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.

The World Health Organization updated its guidelines for the treatment of nonsevere tuberculosis in children after a study showed a four-month duration was noninferior to six months.

The coronavirus pandemic caused the first global recorded decline in human life expectancy.

The federal agency is expected to provide the EUAs prior to their next VRBPAC meeting on April 6.

The public health policies enacted in republican and democratic states have never been more different, and the gulf shows no signs of narrowing.

Both noncarbapenem β-lactams and carbapenems produced good outcomes in UTI from β-lactamase-producing Enterobacterales.

Tori Pipak, a physician assistant at Allegheny Health Network’s Positive Health Clinic, details the comprehensive services the clinic provides to people living with HIV.

Check out the important stories we covered this week.

Treating long-lasting nets with a new insecticidal combination that rendered mosquitos unable to fly reduced malaria infections in Tanzanian children by almost half.

People with immune dysfunction are at increased risk for COVID-19 breakthrough infection after vaccination, and should take additional precautions.

Study of Heartland virus in lone star ticks in Georgia adds to evidence of how it evolves, spreads geographically, and causes disease.

The company is developing a single combination vaccine to cover SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) as well as another candidate for endemic human coronaviruses.

With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.

This designation of the company’s respiratory syncytial virus (RSV) vaccine candidate, PF-06928316, will help to expedite its development and review.

The findings are significant given that a second booster dose may soon be recommended.

Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.

Research set to be presented next month found that people with resolved COVID-19, and in some cases active COVID-19, could safely donate organs.

Along with reporting positive data in the youngest pediatric population, the company is working with the Food and Drug Administration (FDA) for emergency use authorization of its vaccine in children 6 years to under 11 years as well as the 12-17 age groups.

COVID-19 vaccines were less protective against symptomatic infection from the Omicron COVID-19 variant than the Delta variant.

Here’s a roundup of popular foods and products that were recalled this week by the US Food and Drug Administration (FDA).

Series-specific antibiotics can be far less effective if there are other microbes present.

The Omicron variant of SARS-CoV-2 had a secondary attack rate of 25.1% in Norwegian households compared with 19.4% for the Delta variant.